Personal Finance

Is AbbVie Stock Still A Strong Buy?

An excited man staring at his computer.

What happened

Large cap stocks that come with top flight dividends don't normally gain 54% in a single year. However, that's exactly what the dividend aristocrat AbbVie (NYSE: ABBV) did in 2017, according to data from S&P Global Market Intelligence . Thanks to a global patent resolution with Amgen (NASDAQ: AMGN) that removed the immediate threat of copycat versions of Humira entering the U.S. market, AbbVie's stock took off like a rocket last year.

Per the agreement, Amgen will delay the launch of its Humira biosimilar, called Amjevita, in the U.S. until 2023. However, Amgen's drug is scheduled to hit the market in Europe in the fourth-quarter of this year.

An excited man staring at his computer.

Image source: Getty Images.

So what

The key takeaway is that AbbVie now has an extra few years to flesh out its oncology portfolio in an effort to drive growth once Humira's sales do eventually start to slide. Humira, after all, is slated to make up over half of the company's revenues in the next two to three years, despite the strong commercial trajectories for its game-changing blood cancer drugs, Imbruvica and Venclexta.

Now what

AbbVie's strategic long-term goal is to do the unthinkable: Generate industry-leading levels of revenue growth even after its flagship product (Humira) loses exclusivity. Although all of its peers have struggled mightily once their best-selling products started to face generic competition, AbbVie may, in fact, be able to pull off this unprecedented feat. The drugmaker does have an exceptionally deep clinical pipeline in both immunology and oncology, after all. So, despite AbbVie's monstrous rise in 2017, this top dividend and growth stock is arguably still a compelling buy at current levels.

10 stocks we like better than AbbVie

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of January 2, 2018

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABBV AMGN

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More